CVS Health Allergy Relief D Tablets Recalled for Failed Dissolution
CVS Health Allergy Relief D Extended Release Tablets are being recalled because they failed to meet dissolution specifications. The recall affects 41,784 boxes distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. Failed dissolution specifications constitute a labeling/manufacturing defect with potential efficacy concerns but no documented harm, meeting the criteria for Moderate severity.
Plain-English summary
CVS Health Allergy Relief D, containing Fexofenadine HCl 60mg (antihistamine) and Pseudoephedrine HCl 120mg (nasal decongestant), is being recalled due to failed dissolution specifications. The product is supplied in two configurations: 20-count boxes (UPC 050428436189) and 30-count boxes (UPC 050428290538).
The recall affects approximately 41,784 boxes that were distributed nationwide in the USA. The affected lot numbers are: for 20-count boxes, AC2000968A and AC2000968F (expiration 8/31/2022); for 30-count boxes, 79C002624B (expiration 4/30/2022), AC2103330G, and AC2103330H (expiration 1/31/2023). The product was manufactured by Dr. Reddy's Laboratories, Inc. in India and distributed by CVS Pharmacy Inc.
Consumers who have purchased this product should stop using it. Those with questions or concerns should contact their healthcare provider or pharmacist.
The recalled product
- Product
- CVS Health, Allergy Relief D, Fexofenadine HCl 60mg/Antihistamine Pseudoephedrine HCl 120mg/Nasal Decongestant, a) 20 Extended Release Tablets per box, UPC 050428436189, b) 30 Extended Release Tablets per box, UPC 050428290538, Distributed by CVS Pharmacy Inc., One CVS Drive, Wo
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Affected units
- 41,784
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #s: a) (20-count): AC2000968A
- AC2000968F
- Exp. 8/31/2022. b) (30-count): 79C002624B
- Exp. 4/30/2022
- AC2103330G
- AC2103330H
- Exp. 1/31/2023.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 9 recalled by Dr. Reddy's Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 9 products in this recall →Related recalls
Same manufacturer · Dr. Reddy's Laboratories, Inc.
See all →- ModerateVarenicline tablets recalled after an assay value fell below specification
FDA (Drugs) · 2025-12-17
- Moderate
- HighOmeprazole capsule bottle contained a foreign divalproex sodium tablet
FDA (Drugs) · 2025-07-23
- SevereLevetiracetam Injection Label Mismatch Nationwide Recall
FDA (Drugs) · 2025-04-23
- ModerateFDA Recalls JAVYGTOR Tablets Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-12-18
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17